# Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LP-98 Injection in Healthy Subjects

> **NCT05933824** · PHASE1 · COMPLETED · sponsor: **Shanxi Kangbao Biological Product Co., Ltd.** · enrollment: 36 (actual)

## Conditions studied

- HIV (Human Immunodeficiency Virus)

## Interventions

- **DRUG:** LP-98 injection

## Key facts

- **NCT ID:** NCT05933824
- **Lead sponsor:** Shanxi Kangbao Biological Product Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-13
- **Primary completion:** 2024-04-12
- **Final completion:** 2024-04-12
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2026-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05933824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05933824, "Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LP-98 Injection in Healthy Subjects". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT05933824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*